Pulmatrix (PULM) Revenue & Revenue Breakdown
Pulmatrix Revenue Highlights
Latest Revenue (Y)
$7.30M
Latest Revenue (Q)
$1.55M
Main Segment (Y)
Toxicology Study Costs
Main Geography (Y)
Toxicology Study Costs
Pulmatrix Revenue by Period
Pulmatrix Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $7.30M | 20.21% |
| 2022-12-31 | $6.07M | 17.45% |
| 2021-12-31 | $5.17M | -59.09% |
| 2020-12-31 | $12.63M | 59.72% |
| 2019-12-31 | $7.91M | 5069.93% |
| 2018-12-31 | $153.00K | -54.33% |
| 2017-12-31 | $335.00K | -59.88% |
| 2016-12-31 | $835.00K | -30.47% |
| 2015-12-31 | $1.20M | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-03-31 | - | - |
Pulmatrix generated $7.30M in revenue during NA 2023, up 20.21% compared to the previous quarter, and up 4769.93% compared to the same period a year ago.
Pulmatrix Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.55M | -73.63% |
| 2024-03-31 | $5.88M | 167.26% |
| 2023-12-31 | $2.20M | 25.61% |
| 2023-09-30 | $1.75M | -4.93% |
| 2023-06-30 | $1.84M | 23.02% |
| 2023-03-31 | $1.50M | -12.24% |
| 2022-12-31 | $1.71M | -8.76% |
| 2022-09-30 | $1.87M | 40.65% |
| 2022-06-30 | $1.33M | 14.74% |
| 2022-03-31 | $1.16M | 154.39% |
| 2021-12-31 | $456.00K | -57.34% |
| 2021-09-30 | $1.07M | -52.57% |
| 2021-06-30 | $2.25M | 62.16% |
| 2021-03-31 | $1.39M | -30.50% |
| 2020-12-31 | $2.00M | -54.25% |
| 2020-09-30 | $4.37M | 24.91% |
| 2020-06-30 | $3.50M | 26.72% |
| 2020-03-31 | $2.76M | 63.92% |
| 2019-12-31 | $1.69M | 19.84% |
| 2019-09-30 | $1.41M | -70.82% |
| 2019-06-30 | $4.82M | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $153.00K | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2017-09-30 | $335.00K | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $117.00K | 91.80% |
| 2016-09-30 | $61.00K | -76.54% |
| 2016-06-30 | $260.00K | -34.34% |
| 2016-03-31 | $396.00K | 44.00% |
| 2015-12-31 | $275.00K | -57.76% |
| 2015-09-30 | $651.00K | 282.94% |
| 2015-06-30 | $170.00K | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | - |
Pulmatrix generated $1.55M in revenue during Q2 2024, up -73.63% compared to the previous quarter, and up 103.54% compared to the same period a year ago.
Pulmatrix Revenue Breakdown
Pulmatrix Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 20 |
|---|---|
| Toxicology Study Costs | $1.65M |
Pulmatrix's latest annual revenue breakdown by segment (product or service), as of Dec 20: Toxicology Study Costs (100.00%).
Pulmatrix Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 20 |
|---|---|
| Toxicology Study Costs | $1.65M |
Pulmatrix's latest annual revenue breakdown by geography, as of Dec 20: Toxicology Study Costs (100.00%).
Pulmatrix Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ONTX | Traws Pharma | $226.00B | $56.00K |
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| CAPR | Capricor Therapeutics | $25.18M | $3.97M |
| PULM | Pulmatrix | $7.30M | $1.55M |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| CBIO | Gyre Therapeutics | $794.00K | - |
| SLNO | Soleno Therapeutics | - | - |
| BPTH | Bio-Path | - | - |
| MBRX | Moleculin Biotech | - | - |
| TIL | Instil Bio | - | - |
| AKTX | Akari Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| DFFN | CervoMed | - | - |
PULM Revenue FAQ
What is Pulmatrix’s yearly revenue?
Pulmatrix's yearly revenue for 2023 was $7.3M, representing an increase of 20.21% compared to 2022. The company's yearly revenue for 2022 was $6.07M, representing an increase of 17.45% compared to 2021. PULM's yearly revenue for 2021 was $5.17M, representing a decrease of -59.09% compared to 2020.
What is Pulmatrix’s quarterly revenue?
Pulmatrix's quarterly revenue for Q2 2024 was $1.55M, a -73.63% decrease from the previous quarter (Q1 2024), and a -15.84% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $5.88M, a 167.26% increase from the previous quarter (Q4 2023), and a 292.60% increase year-over-year (Q1 2023). PULM's quarterly revenue for Q4 2023 was $2.2M, a 25.61% increase from the previous quarter (Q3 2023), and a 28.92% increase year-over-year (Q4 2022).
What is Pulmatrix’s revenue growth rate?
Pulmatrix's revenue growth rate for the last 3 years (2021-2023) was 41.19%, and for the last 5 years (2019-2023) was -7.74%.
What are Pulmatrix’s revenue streams?
Pulmatrix's revenue streams in c 20 are Toxicology Study Costs
What is Pulmatrix’s main source of revenue?
For the fiscal year ending Dec 20, the largest source of revenue of Pulmatrix was Toxicology Study Costs. This segment made a revenue of $1.65M, representing 100.00% of the company's total revenue.